 Jazz Pharmaceuticals Plc said Wednesday it has agreed to acquire GW Pharmaceuticals Plc in a cash-and-stock deal valued at 7.2 billion. Under the terms of the deal, Jazz Pharma will pay 200 per share in cash and 20 in stock for each share owned, or a premium of about 50 over GWs closing price on Tuesday, and 60 over its 30-day volume weighted average price. 